Adverse events following trivalent inactivated influenza vaccination in children

Analysis of the vaccine adverse event reporting system

Riyadh Muhammad, Penina Haber, Karen R. Broder, Zanie Leroy, Robert Ball, M. Miles Braun, Robert L. Davis, Ann W. McMahon

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The Advisory Committee on Immunization Practices recommendations for influenza vaccination of children have expanded from the long-standing recommendation to vaccinate high-risk children aged 6 months, to vaccinating all 6- to 23-month-olds (2004), 2- to 4-year-olds (2006), and 5- to 18-year-olds (2008). Objective: To identify new or unexpected adverse events (AEs) after trivalent inactivated vaccine (TIV) in children. Methods: We analyzed reports after TIV to the Vaccine Adverse Event Reporting System from 1990-2006 in children aged 2 to 17 years, and from the 2008-2009 influenza season in children aged 5 to 17 years. Empiric Bayesian data mining techniques were used to identify new or unexpected AEs during 1990-2006. Results: During 1990-2006, the Vaccine Adverse Event Reporting System received 2054 reports of children aged 2 to 17 years with a peak in the 2003-2004 influenza season. In 2008-2009, 506 reports describing 5 to 17 year olds were received. The serious reports of tests performed after TIV were approximately 10% of all reports from 2001-2006, and 6% of the reports in the 2008-2009 season. Data mining showed an increased proportion of medication errors and Guillain Barré Syndrome (GBS). The findings of GBS could not be interpreted as causally related to vaccination. Among 201 reports of medication error, 94% had no AE reported other than the medication error itself. Conclusion: In this analysis, we found no unexpected AEs. Our review of medication error and GBS reports suggests that ongoing monitoring in these areas is appropriate.

Original languageEnglish (US)
JournalPediatric Infectious Disease Journal
Volume30
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Human Influenza
Medication Errors
Vaccination
Vaccines
Inactivated Vaccines
Data Mining
Advisory Committees
Immunization

Keywords

  • adverse event
  • influenza vaccine
  • vaccine safety

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Adverse events following trivalent inactivated influenza vaccination in children : Analysis of the vaccine adverse event reporting system. / Muhammad, Riyadh; Haber, Penina; Broder, Karen R.; Leroy, Zanie; Ball, Robert; Braun, M. Miles; Davis, Robert L.; McMahon, Ann W.

In: Pediatric Infectious Disease Journal, Vol. 30, No. 1, 01.01.2011.

Research output: Contribution to journalArticle

Muhammad, Riyadh ; Haber, Penina ; Broder, Karen R. ; Leroy, Zanie ; Ball, Robert ; Braun, M. Miles ; Davis, Robert L. ; McMahon, Ann W. / Adverse events following trivalent inactivated influenza vaccination in children : Analysis of the vaccine adverse event reporting system. In: Pediatric Infectious Disease Journal. 2011 ; Vol. 30, No. 1.
@article{798c4f716d044292a14b50fee6f868c9,
title = "Adverse events following trivalent inactivated influenza vaccination in children: Analysis of the vaccine adverse event reporting system",
abstract = "Background: The Advisory Committee on Immunization Practices recommendations for influenza vaccination of children have expanded from the long-standing recommendation to vaccinate high-risk children aged 6 months, to vaccinating all 6- to 23-month-olds (2004), 2- to 4-year-olds (2006), and 5- to 18-year-olds (2008). Objective: To identify new or unexpected adverse events (AEs) after trivalent inactivated vaccine (TIV) in children. Methods: We analyzed reports after TIV to the Vaccine Adverse Event Reporting System from 1990-2006 in children aged 2 to 17 years, and from the 2008-2009 influenza season in children aged 5 to 17 years. Empiric Bayesian data mining techniques were used to identify new or unexpected AEs during 1990-2006. Results: During 1990-2006, the Vaccine Adverse Event Reporting System received 2054 reports of children aged 2 to 17 years with a peak in the 2003-2004 influenza season. In 2008-2009, 506 reports describing 5 to 17 year olds were received. The serious reports of tests performed after TIV were approximately 10{\%} of all reports from 2001-2006, and 6{\%} of the reports in the 2008-2009 season. Data mining showed an increased proportion of medication errors and Guillain Barr{\'e} Syndrome (GBS). The findings of GBS could not be interpreted as causally related to vaccination. Among 201 reports of medication error, 94{\%} had no AE reported other than the medication error itself. Conclusion: In this analysis, we found no unexpected AEs. Our review of medication error and GBS reports suggests that ongoing monitoring in these areas is appropriate.",
keywords = "adverse event, influenza vaccine, vaccine safety",
author = "Riyadh Muhammad and Penina Haber and Broder, {Karen R.} and Zanie Leroy and Robert Ball and Braun, {M. Miles} and Davis, {Robert L.} and McMahon, {Ann W.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1097/INF.0b013e3181ff9795",
language = "English (US)",
volume = "30",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Adverse events following trivalent inactivated influenza vaccination in children

T2 - Analysis of the vaccine adverse event reporting system

AU - Muhammad, Riyadh

AU - Haber, Penina

AU - Broder, Karen R.

AU - Leroy, Zanie

AU - Ball, Robert

AU - Braun, M. Miles

AU - Davis, Robert L.

AU - McMahon, Ann W.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background: The Advisory Committee on Immunization Practices recommendations for influenza vaccination of children have expanded from the long-standing recommendation to vaccinate high-risk children aged 6 months, to vaccinating all 6- to 23-month-olds (2004), 2- to 4-year-olds (2006), and 5- to 18-year-olds (2008). Objective: To identify new or unexpected adverse events (AEs) after trivalent inactivated vaccine (TIV) in children. Methods: We analyzed reports after TIV to the Vaccine Adverse Event Reporting System from 1990-2006 in children aged 2 to 17 years, and from the 2008-2009 influenza season in children aged 5 to 17 years. Empiric Bayesian data mining techniques were used to identify new or unexpected AEs during 1990-2006. Results: During 1990-2006, the Vaccine Adverse Event Reporting System received 2054 reports of children aged 2 to 17 years with a peak in the 2003-2004 influenza season. In 2008-2009, 506 reports describing 5 to 17 year olds were received. The serious reports of tests performed after TIV were approximately 10% of all reports from 2001-2006, and 6% of the reports in the 2008-2009 season. Data mining showed an increased proportion of medication errors and Guillain Barré Syndrome (GBS). The findings of GBS could not be interpreted as causally related to vaccination. Among 201 reports of medication error, 94% had no AE reported other than the medication error itself. Conclusion: In this analysis, we found no unexpected AEs. Our review of medication error and GBS reports suggests that ongoing monitoring in these areas is appropriate.

AB - Background: The Advisory Committee on Immunization Practices recommendations for influenza vaccination of children have expanded from the long-standing recommendation to vaccinate high-risk children aged 6 months, to vaccinating all 6- to 23-month-olds (2004), 2- to 4-year-olds (2006), and 5- to 18-year-olds (2008). Objective: To identify new or unexpected adverse events (AEs) after trivalent inactivated vaccine (TIV) in children. Methods: We analyzed reports after TIV to the Vaccine Adverse Event Reporting System from 1990-2006 in children aged 2 to 17 years, and from the 2008-2009 influenza season in children aged 5 to 17 years. Empiric Bayesian data mining techniques were used to identify new or unexpected AEs during 1990-2006. Results: During 1990-2006, the Vaccine Adverse Event Reporting System received 2054 reports of children aged 2 to 17 years with a peak in the 2003-2004 influenza season. In 2008-2009, 506 reports describing 5 to 17 year olds were received. The serious reports of tests performed after TIV were approximately 10% of all reports from 2001-2006, and 6% of the reports in the 2008-2009 season. Data mining showed an increased proportion of medication errors and Guillain Barré Syndrome (GBS). The findings of GBS could not be interpreted as causally related to vaccination. Among 201 reports of medication error, 94% had no AE reported other than the medication error itself. Conclusion: In this analysis, we found no unexpected AEs. Our review of medication error and GBS reports suggests that ongoing monitoring in these areas is appropriate.

KW - adverse event

KW - influenza vaccine

KW - vaccine safety

UR - http://www.scopus.com/inward/record.url?scp=78650799872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650799872&partnerID=8YFLogxK

U2 - 10.1097/INF.0b013e3181ff9795

DO - 10.1097/INF.0b013e3181ff9795

M3 - Article

VL - 30

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 1

ER -